Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes.
Alessandro DoriaAndrzej T GaleckiCathie SpinoRodica Pop-BusuiDavid Z CherneyIldiko LingvayAfshin ParsaEllen BurgessRonald J SigalMaryam AfkarianRonnie AronsonM Luiza CaramoriJill P CrandallIan H de BoerThomas G ElliottAllison B GoldfineJ Sonya HawIrl B HirschAmy B KargerDavid M MaahsJanet B McGillMark E MolitchBruce A PerkinsSarit PolskyMarlon PragnellWilliam N RobinerSylvia E RosasPeter SeniorKatherine R TuttleGuillermo E UmpierrezAmisha WalliaRuth S WeinstockChunyi WuMichael Mauernull nullPublished in: The New England journal of medicine (2020)
We found no evidence of clinically meaningful benefits of serum urate reduction with allopurinol on kidney outcomes among patients with type 1 diabetes and early-to-moderate diabetic kidney disease. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others; PERL ClinicalTrials.gov number, NCT02017171.).